Biomarkers in ENT: Facts and Fiction

Editors
Andreas Knopf

Biomarkers are commonly reported endpoints in basic and clinical research trials. However, as technical developments increase the volume and scope of biomarker data, guidance on how to implement this knowledge into daily clinical practice is required. This special topic issue aims to provide such guidance. The current and potential future impact of biomarkers in head and neck oncology, allergology, autoimmunity, imaging techniques, otology, angioedema, and sleep medicine is presented by highly respected experts in these fields. This issue will be an invaluable resource for clinicians looking to carry the latest research findings into their own clinical workup.

Contents

Editorial: Knopf, A.

Introduction
- Individual Biomarkers Using Molecular Personalized Medicine Approaches: Zenner, H.P.

Head and Neck Oncology
- Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond: Höcht, B.; Knolle, P.A.
- CXCR4: A New Player in an Old Scene? Knopf, A.; Fritsche, M.K.; Li, Y.

Head and Neck Autoimmunity

Imaging
- Radiomics in Head and Neck Cancer: Extracting Valuable Information from Data beyond Recognition: Scheckenbach, K.; Colter, L.; Wagenmann, M.

Allergology
- Endotypes in Chronic Rhinosinusitis: Biomarkers Based on a Mechanistic Insight for Targeted Treatment? Wagenmann, M.; Scheckenbach, K.; Chaker, A.M.

Angioedema
- Potential Biomarkers for the Diagnosis of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: Bas, M.; Storck, K.; Strassen, U.

Otology
- Biomarkers for Hearing Dysfunction: Facts and Outlook: Rüttiger, L.; Zimmermann, U.; Knipper, M.
- Vibration-Induced Nystagmus: A Biomarker for Vestibular Deficits – A Synopsis Hamann, K.-F.

Sleep Medicine
- Predictive Success Factors in Selective Upper Airway Stimulation: Heiser, C.; Hofauer, B.

Author Index / Subject Index

The easiest way to order: www.karger.com/orl

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com
Submission

Original papers and reviews written in English are considered for publication. Manuscripts should be submitted to Oncology online and must be accompanied by a cover letter signed by the submitting/corresponding author on behalf of all co-authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication. For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at www.karger.com/ocl, where you will also find a link to the Submission Website. Names, postal and e-mail addresses of at least four experts in the appropriate area of research must accompany each manuscript. Selected scientists will be invited to act as referees. Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject. Should you have any problems with your submission, please contact:

Dr. M. Markman
S. Karger AG
Editorial Office “Oncology”
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1359
Fax +41 61 306 1434
E-Mail ocl@karger.com

Mailing address for courier deliveries only:
Allschwilerstr. 10
CH–4055 Basel (Switzerland)

Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. The editors reserve the right to improve style and, if necessary, return the manuscript for rewriting to the author. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Oncology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

All manuscripts originating from non-English speaking countries must be revised by a professional linguistic reviewer and it must be evident from the covering letter that this has been done. The editor reserves the right to reject papers based on priorities and space availability in the journal.

Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the text of the article.

Ethical and Legal Prerequisites

Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925–926]. Accordingly, the subject’s informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject’s identity is to be avoided.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Categories of Manuscripts

Reviews are comprehensive, state-of-the-art analyses and investigations of important clinical problems. Reviews must include a critical discussion of the reported data and give a clear conclusion with the potential impacts on the standard of care. Reviews may be invited by the Editor, or they may be unsolicited submissions. Reviews are not subject to page charges. The maximum length of manuscripts in this category will be 5,000 words for text and tables (a table = 250 words per page), with a maximum of 5 tables and 50 references.

Clinical Studies and Clinical Translational Research Articles are full-length research papers which will be considered for the journal. These articles cover topics relevant to clinical and translational studies in all oncological fields. Note that manuscripts presenting laboratory-based research efforts must address a clinically relevant issue (Translational Research). Short Communications will focus on descriptions of important toxicities of novel therapies and highly unique oncology-related medical management issues. The maximum length of manuscripts in this category will be 1,000 words.

Clinical Trial Notes are designed for brief discussions of clinical trials, with a particular focus on phase 1, phase 1/2, and phase 2 studies. Priority in this section will not be for studies with a “positive result”, but rather for well-conceived and conducted clinical research efforts. The maximum length of manuscripts submitted in this category will be 1,500 words, with a maximum of 2 tables and 1 figure. The paper should be divided into four sections: Introduction, Methods, Results, Discussion. Note that all manuscripts submitted in this category will undergo rapid review for acceptance or rejection. Reducing the Worldwide Burden of Cancer are country reports describing a variety of regional, national or international efforts that focus on the unique aspects of the epidemiology of cancer, and the delivery of educational messages, preventive services, and oncology-related care within the developing world. Papers submitted for this section benefit from a higher quota of free pages. There are no page charges for papers of 8 or fewer printed pages. Each additional complete or partial page is charged to the author at CHF 325.00.

Editorials are commentaries on current topics or on papers published elsewhere in the issue. Word count limit is 1,500 and 10 references are allowed. They are usually invited by the Editor.

Letters addressed to the Editor are encouraged if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. But letters on general scientific or medical subjects in oncology are also welcome. The length should not exceed 300 words.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Papers submitted to the sections Reviews, Clinical Studies, Clinical Translational Research Articles, Clinical Trial Notes and Reducing the Worldwide Burden of Cancer need an abstract of up to 200 words. Abstracts are recommended, but optional, for Short Communications and Editorials. Abstracts of papers submitted for publication that have clinical implications using human materials should be structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s).

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size: 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions on the Submission Website at www.karger.com/ocl).
Oncology

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References

In the text identify references by Arabic numerals (in square brackets). Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is permissible cost in grant allocation. More information on their grants in the Acknowledgements section of their papers.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com

Include the following statement:

“This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/?doi=[insert DOI number].”

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Page Charges

There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 7 manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Contents

See the journal website for contents
With articles offering an excellent balance between clinical cytology and cytopathology, *Acta Cytologica* fosters the understanding of the pathogenetic mechanisms behind cytomorphology and thus facilitates the translation of frontline research into clinical practice. As the official journal of the International Academy of Cytology and affiliated to over 50 national cytology societies around the world, *Acta Cytologica* evaluates new and existing diagnostic applications of scientific advances as well as their clinical correlations. Original papers, review articles, meta-analyses, novel insights from clinical practice, and letters to the editor cover topics from diagnostic cytopathology, gynecologic and non-gynecologic cytopathology to fine needle aspiration, molecular techniques and their diagnostic applications. As the perfect reference for practical use, *Acta Cytologica* addresses a multidisciplinary audience practicing clinical cytopathology, cell biology, oncology, interventional radiology, otorhinolaryngology, gastroenterology, urology, pulmonology and preventive medicine.

**Acta Cytologica**

*Founded: 1957*  
*Category: Clinical Research*  
*Field of Interest: Cytology*

Listed in bibliographic services, including: PubMed/MEDLINE, Web of Science, Google Scholar, Scopus, Embase

2017: Volume 61  
6 issues per volume  
Language: English  
ISSN 0001–5547  
e-ISSN 1938–2650

**Selected contributions**

- The Pap Test and Bethesda 2014. ‘The reports of my demise have been greatly exaggerated’ (after a quotation from Mark Twain): Nayar, R. (Chicago, Ill.); Wilbur, D.C. (Boston, Mass.)
- Recommendations on Quality Control and Quality Assurance in Cervical Cytology: Branca, M. (Rome); Longatto-Filho, A. (São Paulo/Bareto/Braga/Guimarães)
- Cervical Cytology Reporting Rates from China’s Largest College of American Pathologists-Certified Laboratory with a Focus on Squamous Cell Carcinoma Cytology and Its Histopathological Follow-Up Results: Zheng, B. (Guangzhou); Li, Z. (Columbus, Ohio); Liang, X. (Guangzhou); Austin, R.M. (Pittsburgh, Pa.); Chen, C. (Guangzhou); Zhao, C. (Pittsburgh, Pa.)
- Pathobiology of MicroRNA and Their Emerging Role in Thyroid Fine-Needle Aspiration: Ludviková, M. (Píseň/Prague); Kalfeřt, D. (Hradec Králové); Kholová, I. (Tampere)
- β-Catenin Expression in Oropharyngeal Squamous Cell Carcinomas: Comparison and Correlation with p16 and Human Papillomavirus in situ Hybridization: Nwanze, J.; Cohen, C.; Schmitt, A.C.; Siddiqui, M.T. (Atlanta, Ga.)
179 Polycythemia Vera Management and Challenges in the Community Health Setting
Gerds, A.T. (Cleveland, OH); Dao, K.-H. (Portland, OR)

190 EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience

197 Malignant Mixed Müllerian Tumour of the Uterus: Analysis of 44 Cases
Grasso, S.; Loizzi, V.; Minicucci, V.; Resta, L.; Camporeale, A.L.; Cicinelli, E.; Cormio, G. (Bari)

205 Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

213 Incidence of Histologically Proven Pelvic and Para-Aortic Lymph Node Metastases and Rate of Upstaging in Patients with Locally Advanced Cervical Cancer: Results of a Prospective Randomized Trial
Tsunoda, A.T. (Curitiba); Marnitz, S. (Berlin); Soares Nunes, J. (Curitiba); Mattos de Cunha Andrade, C.E.; Scapulatempo Neto, C. (Barretos); Blohmer, J.-U. (Berlin); Herrmann, J. (Weimar); Kerr, L.M. (Barretos); Martus, P. (Tübingen); Schneider, A. (Berlin); Favero, G.; Köhler, C. (Hamburg)

221 Prognostic Advantage of Docetaxel/Cisplatin/5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence

229 Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma
Camacho, X. (Montevideo); Machado, C.L. (São Paulo); Garcia, M.F.; Gambini, J.P.; Banchero, A.; Fernández, M.; Oddone, N. (Montevideo); Bertolini Zanatta, D.; Rosal, C.; Buchpiguel, C.A.; Chammas, R. (São Paulo); Riva, E.; Cabral, P. (Montevideo)